ResMed Inc. RMD
Healthcare · Medical Instruments & Supplies · United States · S&P 500
Based on the available data, ResMed Inc. gets an algorithmic score of 66/100. It trades at 222.83 $, with a bearish technical trend (RSI 48.1) and 28.4% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (24.3%): generates strong profit on equity.
- High net margin (26.9%): pricing power / competitive advantage.
- Sustained revenue growth (10.2% compound annual).
- Low-debt balance sheet.
- Attractive free-cash-flow yield (5.1%).
- Low beta (0.67): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 21.28 |
| Forward P/E | 16.84 |
| PEG | 1.29 |
| P/B | 4.88 |
| EV/EBITDA | 15.03 |
| P/S | 5.69 |
| ROE % | 24.27 |
| ROA % | 14.00 |
| Gross margin % | 61.62 |
| Operating margin % | 30.86 |
| Net margin % | 26.95 |
| Revenue growth % (y/y) | 8.60 |
| Earnings growth % (y/y) | 2.40 |
| Revenue CAGR % | 10.21 |
| Earnings CAGR % | 19.28 |
| Debt/Equity % | 12.54 |
| Current ratio | 3.10 |
| FCF yield % | 5.07 |
| Dividend yield % | 1.18 |
| Payout % | 23.01 |
Returns
| 1 month | -7.3 % |
| 3 months | +14.7 % |
| 6 months | +1.9 % |
| YTD | -8.2 % |
| 1 year | -16.7 % |
| 3 years | +68.0 % |
| 5 years | -19.1 % |
Risk
| 1-year volatility | 28.4 % |
| Beta | 0.67 |
| 5-year max drawdown | -52.6 % |
| Sharpe 1A | -0.64 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.